What industry does Decart.com belong to?

Decart.com is in the industry of: Pharmaceuticals, Biotechnology, Healthcare.

What tech stack does Decart.com use?

Some of the popular technologies that Decart.com uses are: WordPress, WordPress, OneTrust.

What is Decart.com's estimated annual revenue?

Decart.com's revenue is $9,223,000

What is Decart.com's open headcount?

Decart.com has no job postings yet.

What is the number of ad campaigns for Decart.com?

Decart.com has no advertisements yet.

What is the number of recent news articles about Decart.com?

Decart.com has one news article.

Decart.com - Pubrio Company Profile & Intent

FREE TRIAL - NO CARD NEEDED

Close deals with the right data at the right time.

Pubrio gives your team the data, timing, and tools to reach the right prospects before the competition does.

Company & people search

Filter 560M+ contacts by role, industry, tech stack & more.

Sequences

Automate multi-step outreach without losing the personal touch.

Market signals

Stay ahead of every market shift. Pubrio Signals watches companies for you and delivers the right intelligence.

Start your free trial

Join 9,000+ revenue teams already using Pubrio.

No credit card · Cancel anytime · GDPR safe

Already have an account?Log in

Decart.com

United States · Biotechnology

Pharmaceuticals

Biotechnology

Healthcare

Enhancing CAR T cells with small molecule targeted protein modulation is the scientific foundation of DeCART. Our goal is to modify the underlying CAR T cell biology ex vivo using small molecules to control levels of certain proteins in the T cells. This ex vivo control of protein levels enhances the phenotype of the T cells, referred to as drug-enhanced CAR T cells, which we believe improves CAR T cell therapies and cancer patient outcomes. DeCART Therapeutics is a biotechnology company founded by a team of scientific and business leaders including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., and Xianxin Hua, M.D., Ph.D. from the University of Pennsylvania; Dana M. Hammill, M.S., M.B.A., formally from the University of Pennsylvania and now Chief Operating Officer of DeCART; and, Arthur T. Sands, M.D., Ph.D. and Pierre Beaurang, Ph.D. from Nurix Therapeutics.